STOCKHOLDERS’ EQUITY (Tables)
|
3 Months Ended |
Jun. 30, 2025 |
|---|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF RESTRICTED STOCK AWARDS |
A
summary of the Company’s restricted stock unit awards for the three months ended June 30, 2025 is as follows:
SCHEDULE OF RESTRICTED STOCK AWARDS
| | |
Number Of
Shares | | |
Weighted Average Grant Date Fair Value | |
| | |
| | |
| |
| Unvested as of March 31, 2025 | |
| 18,265 | | |
$ | 139.40 | |
| Granted | |
| - | | |
| - | |
| Vested | |
| - | | |
| - | |
| Forfeited | |
| - | | |
| - | |
| Unvested as of June 30, 2025 | |
| 18,265 | | |
$ | 139.40 | |
|
| SCHEDULE OF FAIR VALUE OF OPTION |
The
following was utilized to calculate the fair value of options on the date of grant:
SCHEDULE OF FAIR VALUE OF OPTION
| | |
June 30, 2025 | | |
June 30, 2024 | |
| Risk-free interest rate | |
| 4.0 – 4.2 | % | |
| 4.3 – 4.5 | % |
| Expected volatility (Beyond Air) | |
| 91.6 – 95.7 | % | |
| 83.5 – 83.8 | % |
| Expected volatility (Beyond Cancer) | |
| - | % | |
| - | % |
| Expected volatility (NeuroNos) | |
| 95.0 | % | |
| - | % |
| Dividend yield | |
| 0 | % | |
| 0 | % |
| Expected terms (in years) | |
| 6.25 | | |
| 6.25 | |
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE |
The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three months ended June 30, 2025 and June 30, 2024:
SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE
| | |
2025 | | |
2024 | |
| | |
Three Months Ended | |
| (in thousands) | |
June 30, | |
| | |
2025 | | |
2024 | |
| | |
| | |
| |
| Research and development | |
$ | 300 | | |
$ | 629 | |
| General and administrative | |
| 1,277 | | |
| 2,750 | |
| Total stock-based compensation expense | |
$ | 1,577 | | |
$ | 3,379 | |
|
| SUMMARY OF COMPANY’S OUTSTANDING WARRANTS |
A
summary of the Company’s outstanding warrants as of June 30, 2025 is as follows:
SUMMARY
OF COMPANY’S OUTSTANDING WARRANTS
| Warrant Holders | |
Number of Warrants | | |
Exercise Price | | |
Intrinsic Value (in thousands) | | |
Date of Expiration |
| | |
| | |
| | |
| | |
|
| NitricGen agreement | |
| 4,000 | | |
$ | 138.00 | | |
| - | | |
January 2028 |
| Avenue agreement | |
| 11,693 | | |
$ | 7.59 | | |
| - | | |
June 2028 |
| March 2024 raise | |
| 481,936 | | |
$ | 45.00 | | |
| - | | |
March 2027 |
| Avenue extension agreement | |
| 5,000 | | |
$ | 25.60 | | |
| - | | |
June 2029 |
| September 2024 equity offering | |
| 1,994,360 | | |
$ | 7.59 | | |
| - | | |
September 2029 |
| September 2024 debt instrument | |
| 757,977 | | |
$ | 7.59 | | |
| - | | |
September 2029 |
| Sub-total | |
| 3,254,966 | | |
$ | 13.31 | | |
$ | - | | |
|
| | |
| | | |
| | | |
| | | |
|
| Pre-funded warrants | |
| 606,367 | | |
$ | 0.002 | | |
$ | 2,088 | | |
September 2029 |
| Total | |
| 3,861,333 | | |
$ | 11.22 | | |
$ | 2,088 | | |
|
|
| 2013 Beyond Air Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for the three months ended June 30, 2025 is as follows:
SCHEDULE OF OPTION ACTIVITY
| | |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (in thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2025 | |
| 739,219 | | |
$ | 9.34 | | |
| 7.9 | | |
$ | - | |
| Granted | |
| 2,050 | | |
| 5.89 | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (13,007 | ) | |
| 9.28 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2025 | |
| 728,262 | | |
$ | 9.33 | | |
| 7.7 | | |
$ | - | |
| Exercisable as of June 30, 2025 | |
| 308,737 | | |
$ | 10.80 | | |
| 5.8 | | |
$ | - | |
|
| 2021 Beyond Cancer Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
SCHEDULE
OF OPTION ACTIVITY FOR BEYOND
CANCER
| | |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2025 | |
| 2,816,250 | | |
$ | 5.50 | | |
| 7.2 | | |
$ | - | |
| Granted | |
| - | | |
| - | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (404,250 | ) | |
| 5.50 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2025 | |
| 2,412,000 | | |
$ | 5.50 | | |
| 6.9 | | |
$ | - | |
| Exercisable as of June 30, 2025 | |
| 1,504,000 | | |
$ | 5.50 | | |
| 6.8 | | |
$ | - | |
|
| 2025 NeuroNos Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for NeuroNos for the three months ended June 30, 2025 is as follows:
SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS
| | |
Number of Options | | |
Weighted Average Exercise Price of Options | | |
Weighted Average Remaining Contractual Life of Options | | |
Aggregate Intrinsic Value (thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2025 | |
| 1,224,139 | | |
$ | 0.14 | | |
| 9.0 | | |
$ | 3,501 | |
| Granted | |
| 156,000 | | |
| 3.00 | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (1,435 | ) | |
| 0.14 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2025 | |
| 1,378,704 | | |
$ | 0.46 | | |
| 8.5 | | |
$ | 3,497 | |
| Exercisable as of June 30, 2025 | |
| 306,035 | | |
$ | 0.14 | | |
| 8.8 | | |
$ | 875 | |
|